NCT/Study#
NCT06246916 /
R3767-ONC-22122
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma
DISEASE GROUP:
Skin and Soft Tissue
current phase:
Phase III
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
